Accelerating the Development and Uptake of Rapid Diagnostics to Address Antibiotic Resistance Proceedings of a Workshop (2023) / Chapter Skim
Currently Skimming:
Appendix B: Biographical Sketches of the Workshop Planning Committee and Speakers
Appendix B: Biographical Sketches of the Workshop Planning Committee and Speakers
Pages 109-126
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 109... ...
from the Sidney Kimmel Medical College, Thomas Jefferson University, completing his internship and residency in internal medicine at the University of Maryland and a research fellowship in infectious diseases at the Walter Reed Army Medical Center. Currently a member of the U.S.
|
From page 110... ...
John Billington, J.D., M.P.H., is Head of Commercial Pipeline and Health Security Policy and Advocacy in the global corporate government affairs department of GSK. In this role, he is responsible for the company's policy and advocacy strategy for the commercial pipeline at the enterprise level, including a focus on pandemic preparedness and antimicrobial resistance (AMR)
|
From page 111... ...
Louis and the program director for the Medical and Public Health Microbiology Fellowship at Washington University. At Washington University, her research program focused on the development of new diagnostics for infectious diseases, antimicrobial resistance, and transmission and epidemiology of antimicrobial resistant microorganisms.
|
From page 112... ...
, which represents more than 12,000 ID physicians and scientists. Amanda oversees IDSA's public policy and government relations department, with responsibility for policy development and advocacy on IDSA priority issues, including antimicrobial resistance, the infectious diseases workforce, pandemic preparedness and response, immunizations, federal funding, and other issues relating to public health and biomedical research.
|
From page 113... ...
Dr. Patel is a Fellow of American Academy of Microbiology, Past President of the American Society for Microbiology, a past associate editor for Clinical Infectious Diseases, and course director for the Mayo Clinic Alix School of Medicine microbiology.
|
From page 114... ...
Louis and then completed Pediatrics residency and Pediatric Infectious Disease fellowship at the University of California, San Francisco. She is a member of many national committees through the Pediatric Infectious Diseases Society, the American Academy of Pediatrics, the Infectious Diseases Society of America, and the Antibacterial Resistance Leadership Group.
|
From page 115... ...
John Billington, J.D., M.P.H., is Head of Commercial Pipeline and Health Security Policy and Advocacy in the global corporate government affairs department of GSK. In this role, he is responsible for the company's policy and advocacy strategy for infectious diseases at the enterprise level, with a focus on pandemic preparedness and antimicrobial resistance (AMR)
|
From page 116... ...
Karen Carroll, M.D., is professor of pathology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include medical microbiology and infectious diseases.
|
From page 117... ...
For that he won the Qiagen Sydney Brenner R&D Award for outstanding accomplishment in global R&D. He completed postdoctoral fellowships in nuclear tRNA transport at the Howard Hughes Medical Institute at the University of Pennsylvania and in catalytic RNA with Nobel laureate Sidney Altman at the Department of Biology at Yale University.
|
From page 118... ...
Greg Frank, Ph.D., is Director, Global Public Policy with Merck, where he leads Merck's global antimicrobial resistance (AMR) policy.
|
From page 119... ...
Department of Homeland Security and as a scientific editor and consultant. She has over a decade of experience in federal and global policy and advocacy work and has authored numerous publications on pandemic preparedness, antimicrobial resistance, molecular diagnostics, and biomedical R&D.
|
From page 120... ...
He has interests in diagnostic stewardship, antimicrobial resistance, and working on topics at the intersection of clinical infectious diseases and the microbiology laboratory. Alita Miller, Ph.D., is the Chief Scientific Officer at Entasis Therapeutics, where she has played a key role in the discovery and development of several novel antibacterial agents, including ETX0462, sulbactam- durlobactam and zoliflodacin.
|
From page 121... ...
Dr. Patel is a Fellow of the American Academy of Microbiology, past president of the American Society for Microbiology, a past associate editor for Clinical Infectious Diseases, and course director for the Mayo Clinic Alix School of Medicine microbiology course.
|
From page 122... ...
. The ARLG is a National Institutes of Health sponsored initiative that supports a national network of scientists to develop, implement, and manage a clinical research agenda to combat the public health crisis of antimicrobial resistance.
|
From page 123... ...
As a medical doctor, he has extensive experience across both private and public sectors, founding his own diagnostics company, Daktari Diagnostics -- a venture-backed start-up company developing portable diagnostics for HIV, HCV, tuberculosis, typhoid, and maternal health for use in low- and middle-income countries. He is a highly respected figure in the global health community, serving as advisor to the World Health Organization, Bill & Melinda Gates Foundation, national governments on global HIV, tuberculosis, Ebola and COVID-19, as well as numerous established and start-up for-profit and not-for-profit social enterprises focused on global health.
|
From page 124... ...
This would prove to be the inflection point in Shader Smith's life as this catastrophic loss would lead her on a new path, one that was both unexpected and transformative. Since then, Shader Smith's work has used Mallory's posthumously published memoir, Salt in My Soul, and the documentary of the same name to address the following topics: AMR and the urgent global health crisis antimicrobial resistance poses, phage therapy, the power of the patient voice, the opioid epidemic and the need for balance, insurance obstacles and access to healthcare, narrative medicine, storytelling to improve health outcomes, the role of the caregiver, and memoir as medicine.
|
From page 125... ...
President's Council of Advisors in Science and Technology and as part of the WHO expert Technical Consultation on In Vitro Diagnostics for Antimicrobial Resistance. His research and policy work on collaborative R&D models and incentives for innovation has received support under a Robert Wood Johnson Investigator Award in Health Policy Research. He contributed to the Lancet Infectious Diseases Commission on Antibiotic Resistance, co-edited the Chatham House's Working Group's report, Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales, and co-authored "A Framework for Costing the Lowering of Antimicrobial Use in Food Animal Production" for the UK Review on Antimicrobial Resistance.
|
From page 126... ...
, bacterial identification & antibiotic susceptibility, enteric diseases, respiratory diseases, sexually transmitted infections, and oncology. Over the past 18 years, Dr.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.